- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06363071
APA and PAS Training for Gait Initiation in Parkinson's Disease
Gait-initiation Related APA Training in Individuals With Parkinson Disease -Explicit Training and Paired Associative Stimulation(PAS) Priming
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Research on Brain Excitability and Balance Function Performance in Patients with Parkinson's Disease and Related Physical Therapy Methods
Research indicates that non-motor disorders and cognitive impairments are prevalent in most patients with Parkinson's disease. These include balance issues, postural instability, impaired cognitive functions like working memory and executive functions, and gait instability. Additionally, electrophysiological phenomena in Parkinson's disease patients reveal abnormal central excitatory and inhibitory responses compared to healthy individuals.
This experiment seeks to investigate the link between motor performance and brain excitability in patients with Parkinson's disease. Previous studies suggest that associative electrical stimulation, used to regulate sensorimotor information integration, can enhance brain excitability in both healthy individuals and those with Parkinson's disease. However, the optimal parameters for this stimulation remain uncertain.
Furthermore, balance exercise training can improve motor performance in Parkinson's disease patients. This study aims to determine if various designs of associative electrical stimulation parameters can help these patients achieve optimal brain excitability regulation. The combined approach of this stimulation and balance exercise training aims to maintain and improve the patients' functional performance, thereby enhancing the safety of their daily activities.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ya-Ju Chang, PhD
- Phone Number: 5515 +88632118800
- Email: yjchang@mail.cgu.edu.tw
Study Locations
-
-
-
Taoyuan, Taiwan, 333
- Recruiting
- Chang Gung University
-
Contact:
- Ya-Ju Chang, PhD
- Phone Number: 5515 88632118800
- Email: yjchang@mail.cgu.edu.tw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Health subjects:
Exclusion Criteria:
- Musculoskeletal injuries on legs.
- Osteoporosis.
PD subjects:
Inclusion Criteria:
- Clinical diagnosis of Parkinson disease.
Exclusion Criteria:
- Musculoskeletal injuries on legs
- Osteoporosis.
- Any peripheral or central nervous system injury or disease patients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Stage 1:Healthy people
To establish PAS baseline and reliability.
|
Use TMS combine ES to stimulate TA nerve and M1 cortical
Other Names:
|
|
Experimental: Stage 2:PD people
To establish stage 3 training protocol.
|
Use TMS combine ES to stimulate TA nerve and M1 cortical
Other Names:
|
|
No Intervention: Stage 3:PD people
Control group.
|
|
|
Experimental: Stage 3: PD APA training group
Weight shift training and APA feedback.
|
Use COP trajectory to train weight shift on force plate.
To give APA visual feedback for subjects after weight shift training.
Other Names:
|
|
Experimental: Stage 3:PD PAS group
Using PAS to regulate brain plasticity
|
Use TMS combine ES to stimulate TA nerve and M1 cortical
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Balance Performance
Time Frame: Baseline, 4 weeks and 8 weeks.
|
Measured by the duration the stance can be maintained.
Unit:seconds(s)
|
Baseline, 4 weeks and 8 weeks.
|
|
COP Path Length in Balance Tasks
Time Frame: Baseline, 4 weeks and 8 weeks.
|
The total distance traveled by the COP over a specified period.
Longer path lengths can indicate increased effort to maintain balance or greater instability.
Unit:millimeters(mm)
|
Baseline, 4 weeks and 8 weeks.
|
|
COP Displacement in Balance Tasks
Time Frame: Baseline, 4 weeks and 8 weeks.
|
Measures of COP movement in the anterior-posterior (AP) and medial-lateral (ML) directions, offering insights into the directional tendencies of balance control.
Unit:millimeters(mm)
|
Baseline, 4 weeks and 8 weeks.
|
|
Motor Evoked Potentials (MEPs)
Time Frame: Baseline, 4 weeks and 8 weeks.
|
MEPs are the electrical responses recorded from muscles following stimulation of the motor cortex.
They reflect the efficiency of neural transmission from the cortex to the muscle.
Unit:millivolts (mV)
|
Baseline, 4 weeks and 8 weeks.
|
|
Intracortical Facilitation (ICF)
Time Frame: Baseline, 4 weeks and 8 weeks.
|
ICF is measured by applying a pair of TMS pulses with a short interval (e.g., 8-15 ms) where the first (subthreshold) pulse is followed by a second (suprathreshold) pulse, leading to an increased amplitude of the MEP.
|
Baseline, 4 weeks and 8 weeks.
|
|
Intracortical Inhibition (ICI)
Time Frame: Baseline, 4 weeks and 8 weeks.
|
ICI is measured similarly to ICF but with a shorter inter-stimulus interval (e.g., 1-5 ms), resulting in a suppressed MEP amplitude.
This suppression reflects inhibitory processes within the cortex.
|
Baseline, 4 weeks and 8 weeks.
|
|
Walking Speed
Time Frame: Baseline, 4 weeks and 8 weeks.
|
The time taken by participants to walk a standardized distance, typically expressed in centimeters per second (cm/s).
|
Baseline, 4 weeks and 8 weeks.
|
|
Step Length
Time Frame: Baseline, 4 weeks and 8 weeks.
|
The linear distance between the two ankles, typically expressed in centimeter(cm).
|
Baseline, 4 weeks and 8 weeks.
|
|
Step Time
Time Frame: Baseline, 4 weeks and 8 weeks.
|
The duration taken for one complete step, measuring from foot-off of one foot to the next foot-off of the same foot, usually expressed in seconds.
|
Baseline, 4 weeks and 8 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
COP Velocity in Balance Tasks
Time Frame: Baseline, 4 weeks and 8 weeks.
|
The speed at which the COP moves, calculated over the duration of the balance task.
Higher velocities may reflect more dynamic balance adjustments or instability.
Unit:millimeters per second(mm/s)
|
Baseline, 4 weeks and 8 weeks.
|
|
COP Area in Balance Tasks
Time Frame: Baseline, 4 weeks and 8 weeks.
|
The area covered by the COP trajectory during the balance task, providing an estimate of the sway envelope.
A larger area might indicate poorer balance control.
Unit:square millimeters(mm^2)
|
Baseline, 4 weeks and 8 weeks.
|
|
Double Support Time
Time Frame: Baseline, 4 weeks and 8 weeks.
|
The portion of the gait cycle where both feet are in contact with the ground, indicating the transition phase between steps, expressed as a percentage of the gait cycle or in seconds.
|
Baseline, 4 weeks and 8 weeks.
|
|
Single Support Time
Time Frame: Baseline, 4 weeks and 8 weeks.
|
The duration within the gait cycle when only one foot is in contact with the ground, typically measured in seconds or as a percentage of the total gait cycle.
|
Baseline, 4 weeks and 8 weeks.
|
|
Swing Time
Time Frame: Baseline, 4 weeks and 8 weeks.
|
The portion of the gait cycle where the foot is not in contact with the ground, moving forward to the next step.
It is usually expressed as a percentage of the total gait cycle or in seconds.
|
Baseline, 4 weeks and 8 weeks.
|
|
Stance Time
Time Frame: Baseline, 4 weeks and 8 weeks.
|
The portion of the gait cycle when the foot is in contact with the ground, supporting body weight.
It's typically expressed as a percentage of the total gait cycle or in seconds
|
Baseline, 4 weeks and 8 weeks.
|
|
Cadence
Time Frame: Baseline, 4 weeks and 8 weeks.
|
The number of steps an individual takes per minute, providing an overview of gait speed and rhythm, , expressed as steps per minute.
|
Baseline, 4 weeks and 8 weeks.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202000495A3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
Bezmialem Vakif UniversityRecruitingParkinson Disease | Parkinson | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseTurkey (Türkiye)
-
CND Life SciencesDigestive Disease Associates of CTRecruitingParkinson Disease | Parkinson | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Neuron23 Inc.Roche Diagnostic Ltd.; Qiagen Manchester LimitedRecruitingParkinson Disease | Parkinson | Idiopathic Parkinson Disease | Parkinson Disease, Idiopathic | Early Parkinson Disease (Early PD)United States, Spain, Israel, Poland, Italy, United Kingdom
-
San Francisco Neurology and Sleep CenterNot yet recruitingPARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Haukeland University HospitalUniversity of Bergen; SPARK NSRecruitingParkinson Disease (PD) | Parkinson s DiseaseNorway
-
CND Life SciencesOregon Health and Science UniversityRecruitingParkinson Disease | Parkinson | Parkinson's Disease and Parkinsonism | PARKINSON DISEASE (Disorder)United States
-
Università degli Studi dell'InsubriaUniversidade Nova de Lisboa; Associazione Parkinson Insubria (AsPI), Section... and other collaboratorsRecruitingParkinson Disease | Parkinson | Parkinson Disease, Idiopathic | PARKINSON DISEASE (Disorder)Italy
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
Duke UniversityMedical University of South Carolina; Massachusetts General Hospital; Mayo Clinic and other collaboratorsNot yet recruitingGut Microbiota | Gut Microbiome | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Prodromal Parkinsons DiseaseUnited States
-
ProgenaBiomeWithdrawnParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
Clinical Trials on Weight shift training and APA feedback
-
Chang Gung UniversityCompleted
-
Chang Gung UniversityRecruiting
-
KU LeuvenCompletedHealthy AgingBelgium
-
University of North Carolina, Chapel HillLSVT GlobalCompletedParkinson DiseaseUnited States
-
University of VirginiaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2United States
-
The University of Texas Health Science Center,...Johns Hopkins University; National Cancer Institute (NCI)Active, not recruitingChemotherapy-induced NeuropathyUnited States
-
The Miriam HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Unknown
-
Unity Health TorontoHeart and Stroke Foundation of Canada; Zoll Medical CorporationCompletedCardiopulmonary ResuscitationCanada
-
University of ConnecticutNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University...Recruiting
-
Towson UniversityCompletedOverweight and ObesityUnited States